Diabetologia

Exenatide Versus Lantus

In the therapeutic equipment of type-2 diabetics, exenatide has recently appeared, an agonist of glucagone-like peptide (GLP-1) receptors; its mechanism of action lies in the stimulus of glucose-dependent insulin secretion, in reducing glucagone secretion and in slowing down the period of gastric emptying, with the consequent decrease of food intake. The FDA has approved its daily formulation (two injections a day), but it was shown that a single weekly injection is more effective in reducing HbA1c and in obtaining weight loss.
Approfondisci

 http://mn.medsurfnews.com/contents/en/6119/display/exenatide...

MedNews